IL28B polymorphisms predict treatment response in chronic hepatitis C. However, no information exists in prior treatment failures. A total of 62 HIV/hepatitis C virus (HCV) patients who completed retreatment with peginterferon-α/ribavirin were examined, of whom 25 (40%) had been cured. Predictors of response [odds ratio, OR (95% confidence interval, CI)] were HCV genotypes 2/3 [16.1 (2.7–90.9)], prior relapse [9.6 (1.5–62.4)] and ribavirin plasma trough concentrations at week 4 [4.9 (1.3–18.4)]. IL28B-CC only predicted response in prior nonresponders carrying HCV genotypes 1/4 [25.1 (1.9–337)].
aHospital Carlos III, Madrid, Spain
bHospital Valme, Seville, Spain
cHospital Reina Sofía, Córdoba, Spain
dUniversidad de Jaén, Jaén, Spain
eHospital San Pedro, Logroño, Spain.
Received 16 February, 2011
Revised 10 March, 2011
Accepted 24 March, 2011
Correspondence to Dr Pablo Barreiro, Department of Infectious Diseases, Hospital Carlos III, Calle Sinesio Delgado 10, Madrid 28029, Spain. Tel: +34 91 4532500; fax: +34 91 7336614; e-mail: email@example.com